Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors

This publication has 54 references indexed in Scilit:

• Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca.
  The American Journal of Cardiology, 2001
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Cerivastatin in the treatment of mixed hyperlipidemia: the right study
  The American Journal of Cardiology, 1998
• Pravastatin‐induced rhabdomyolysis in a patient with mixed connective tissue disease
  Arthritis & Rheumatism, 1996
• Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study
  The Journal of Clinical Pharmacology, 1993
• Experimental Evaluation of the Effects of Pravastatin on Electrophysiological Parameters of Rat Skeletal Muscle
  Basic & Clinical Pharmacology & Toxicology, 1992
• Regulation of the mevalonate pathway
  Nature, 1990
• HMG CoA Reductase Inhibitors
  Drugs, 1988
• Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers
  Journal of Medicinal Chemistry, 1987
• Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia
  New England Journal of Medicine, 1981